PATENT CLAIM ANALYSIS

Application Number: 15779435
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "235800"]

Abstract:
The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R 1  represents a hydrogen atom, an optionally substituted alkyl group, or the like; R 2  represents a hydrogen atom, a halogen atom, or the like; and R 3  represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Claim (Index 4):
The compound according to  claim 2 , wherein\n said aryl moiety in the optionally substituted aryl group represented by Ring A is phenyl or naphthyl; said heteroaryl moiety in the optionally substituted heteroaryl group represented by Ring A is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl; said aryl moiety in the optionally substituted aryl group represented by R 1  is phenyl or naphthyl; said heteroaryl moiety in the optionally substituted heteroaryl group represented by R 1  is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group represented by R 1  is azetidinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, homopiperazinyl, homomorpholinyl, 3-azabicyclo[3.1.0]hexyl, or octahydropyrrolo[3,4-c]pyrrolyl; said aryl moiety in the optionally substituted aryl group in the substituent of the group represented by R 1  is phenyl or naphthyl; said heteroaryl moiety in the optionally partially hydrogenated and optionally substituted heteroaryl group in the substituent of the group represented by R 1  is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group in the substituent of the group represented by R 1  is azetidinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, homopiperazinyl, homomorpholinyl, 3-azabicyclo[3.1.0]hexyl, or octahydropyrrolo[3,4-c]pyrrolyl; the aryl group represented by Ring B is phenyl or naphthyl; the heteroaryl group represented by Ring B is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl; said heteroaryl moiety in the optionally substituted heteroaryl group represented by R 4 , R 5 , or R 6  is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl; said aliphatic heterocyclic moiety in the optionally substituted aliphatic heterocyclic group represented by R 4 , R 5 , or R 6  is azetidinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, homopiperazinyl, homomorpholinyl, 3-azabicyclo[3.1.0]hexyl, or octahydropyrrolo[3,4-c]pyrrolyl; and said heteroaryl moiety in the optionally substituted heteroaryl group in the substituent of the group represented by R 4 , R 5 , or R 6  is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, quinolyl, isoquinolyl, isoindolyl, or benzimidazolyl, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 93.0
- Lexical Diversity: 2.03846
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15313407', '15305587', '13154144', '12919973', '14891845']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.745829327714148
- 35 USC 102 Novelty (BERT): 0.5616691809304385
- Combined Prediction Score: 0.727413313035777
- Mean Citation Score: 313.940092
- Max Citation Score: 427.80472
- Similarity Product: 331.0278021957588

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test